Pfizer Inc. said its Covid-19 vaccine was granted priority review by U.S. regulators, putting it on track for a potential full approval by early next year.
The drugmaker and its German partner BioNTech SE said in a statement Friday that the Food and Drug Administration plans to decide whether to approve the shot for use in people 16 and older by January 2022.
Shares of Pfizer gained 0.2% at 11:41 a.m. in New York trading, while BioNTech’s U.S. stock climbed 3.7%.
Pfizer’s vaccine has been administered to more Americans than any other shot so far in the U.S. immunization campaign. ...